Evaluation of near point-of-care viral load implementation in public health facilities across seven countries in sub-Saharan Africa

Caroline E Boeke, Jessica Joseph, Charles Atem, Clement Banda, Khady Diatou Coulibaly, Naoko Doi, Andrews Gunda, James Kandulu, Brianán Kiernan, Leonard Kingwara, Werner Maokola, Tatenda Maparo, Rose Nadege Mbaye, Esther Mtumbuka, Joseph Mziray, Catherine Ngugi, Jeanine Nkakulu, Divine Nzuobontane, Marie Claire Okomo Assoumo, Trevor Peter, Maria R Rioja, Jilian A Sacks, Raiva Simbi, Lara Vojnov, Shaukat A Khan, Caroline E Boeke, Jessica Joseph, Charles Atem, Clement Banda, Khady Diatou Coulibaly, Naoko Doi, Andrews Gunda, James Kandulu, Brianán Kiernan, Leonard Kingwara, Werner Maokola, Tatenda Maparo, Rose Nadege Mbaye, Esther Mtumbuka, Joseph Mziray, Catherine Ngugi, Jeanine Nkakulu, Divine Nzuobontane, Marie Claire Okomo Assoumo, Trevor Peter, Maria R Rioja, Jilian A Sacks, Raiva Simbi, Lara Vojnov, Shaukat A Khan

Abstract

Introduction: In many low- and middle-income countries, HIV viral load (VL) testing occurs at centralized laboratories and time-to-result-delivery is lengthy, preventing timely monitoring of HIV treatment adherence. Near point-of-care (POC) devices, which are placed within health facility laboratories rather than clinics themselves (i.e. "true" POC), can offer VL in conjunction with centralized laboratories to expedite clinical decision making and improve outcomes, especially for patients at high risk of treatment failure. We assessed impacts of near-POC VL testing on result receipt and clinical action in public sector programmes in Cameroon, Democratic Republic of Congo, Kenya, Malawi, Senegal, Tanzania and Zimbabwe.

Methods: Routine health data were collected retrospectively after introducing near-POC VL testing at 57 public sector health facilities (2017 to 2019, country-dependent). Where possible, key indicators were compared to data from patients receiving centralized laboratory testing using hazard ratios and the Somers' D test.

Results: Data were collected from 6795 tests conducted on near-POC and 17614 tests on centralized laboratory-based platforms. Thirty-one percent (2062/6694) of near-POC tests were conducted for high-risk populations: pregnant and breastfeeding women, children and those with suspected failure. Compared to conventional testing, near-POC improved the median time from sample collection to return of results to patient [six vs. sixty-eight days, effect size: -32.2%; 95% CI: -41.0% to -23.4%] and to clinical action for individuals with an elevated HIV VL [three vs. fourty-nine days, effect size: -35.4%; 95% CI: -46.0% to -24.8%]. Near-POC VL results were two times more likely to be returned to the patient within 90 days compared to centralized tests [50% (1781/3594) vs. 27% (4172/15271); aHR: 2.22, 95% CI: 2.05 to 2.39]. Thirty-seven percent (340/925) of patients with an elevated near-POC HIV VL result had documented clinical follow-up actions within 30 days compared to 7% (167/2276) for centralized testing.

Conclusions: Near-POC VL testing enabled rapid test result delivery for high-risk populations and led to significant improvements in the timeliness of patient result receipt compared to centralized testing. While there was some improvement in time-to-clinical action with near-POC VL testing, major gaps remained. Strengthening of systems supporting the utilization of results for patient management are needed to truly capitalize on the benefits of decentralized testing.

Keywords: Africa; point of care; viral load monitoring; viral suppression.

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Kaplan‐Meier curves showing (a) receipt of results at the health clinic; (b) receipt of results by patients; (c) receipt of elevated HIV VL results by patients (d) clinical action of elevated HIV VL results, all for near‐POC HIV VL testing compared to centralized laboratory testing.
Figure 2
Figure 2
Kaplan‐Meier curve showing clinical action taken for (a) children and (b) pregnant and breastfeeding women with an elevated HIV VL monitored using near‐POC HIV VL testing compared to centralized laboratory testing.

References

    1. WHO . Consolidated guidelines on the use of antiretroviral therapy for treating and preventing HIV infection: recomendations for a public health approach, Seond edn. Geneva: World Health Organization; 2016.
    1. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258–71.
    1. Quinn TC, Wawer MJ, Sewankambo N,Serwadda D, Li C, Wabwire‐Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9.
    1. Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, et al. Estimating the impact of plasma HIV‐1 RNA reductions on heterosexual HIV‐1 transmission risk. PLoS One. 2010;5:e12598.
    1. HIV Market Report. Clinton Health Access Initiative; 2019.
    1. Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated viral load: a systematic review and meta‐analysis. J Int AIDS Soc. 2019;22:e25415.
    1. Fox MP, Brennan AT, Nattey C, MacLeod WB, Harlow A, Mlisana K, et al. Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. J Int AIDS Soc. 2020;23:e25542.
    1. Sandbulte M, Brown M, Wexler C, Maloba M, Gautney B, Goggin K, et al. Maternal viral load monitoring: coverage and clinical action at 4 Kenyan hospitals. PLoS One. 2020;15:e0232358.
    1. Drain PK, Dorward J, Bender A, Lillis L, Marinucci F, Sacks J, et al. Point‐of‐care HIV viral load testing: an essential tool for a sustainable global HIV/AIDS response. Clin Microbiol Rev. 2019;32(3):18.
    1. Dorward J, Drain PK, Garrett N. Point‐of‐care viral load testing and differentiated HIV care. Lancet HIV. 2018;5(1):e8–e9.
    1. Nicholas S, Poulet E, Wolters L,Wapling J, Rakesh A, Amoros L, et al. Point‐of‐care viral load monitoring: outcomes from a decentralized HIV programme in Malawi. J Int AIDS Soc. 2019;22:e25387.
    1. Ganesh P, Heller T, Chione B, Gumulira J, Gugsa S, Khan S, et al. Near point of care HIV viral load: targeted testing at large facilities. J Acquir Immune Defic Syndr. 2020;22:e25387.
    1. Girdwood SJ, Nichols BE, Moyo C, Crompton T, Chimhamhiwa D, Rosen S. Optimizing viral load testing access for the last mile: Geospatial cost model for point of care instrument placement. PLoS One. 2019;14:e0221586.
    1. Newson R. Parameters behind “nonparametric” statistics: Kendall’s tau, Somers’ D and median differences. The Stata Journal. 2002;2(1):45–64.
    1. Drain PK, Dorward J, Violette LR, Quame‐Amaglo J, Thomas KK, Samsunder N, et al. Point‐of‐care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open‐label, non‐inferiority, randomised controlled trial. Lancet HIV. 2020;7(4):e229–e237.
    1. Villa G, Abdullahi A, Owusu D, Smith C, Azumah M, Sayeed L, et al. Determining virological suppression and resuppression by point‐of‐care viral load testing in a HIV care setting in sub‐Saharan Africa. EClinicalMedicine. 2020;18:100231.
    1. Gueguen M, Nicholas S, Poulet E,Schramm B, Szumilin E, Wolters L, et al. Implementation and operational feasibility of SAMBA I HIV‐1 semi‐quantitative viral load testing at the point of care in rural settings in Malawi and Uganda. Trop Med Int Health. 2020. 10.1111/tmi.13519 [Epub ahead of print].
    1. Kufa T, Mazanderani AH, Sherman GG, Mukendi A, Murray T, Moyo F, et al. Point‐of‐care HIV maternal viral load and early infant diagnosis testing around time of delivery at tertiary obstetric units in South Africa: a prospective study of coverage, results return and turn‐around times. J Int AIDS Soc. 2020;23:e25487.
    1. Boeke CE, Nabitaka V, Rowan A, Guerra K, Nawaggi P, Mulema V, et al. Results from a proactive follow‐up intervention to improve linkage and retention among people living with HIV in Uganda: a pre‐/post‐ study. BMC Health Serv Res. 2018;18(1):949.
    1. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376(9755):1838–45.
    1. Scanlon ML, Vreeman RC. Current strategies for improving access and adherence to antiretroviral therapies in resource‐limited settings. HIV AIDS (Auckl). 2013;5:1–17.

Source: PubMed

3
Předplatit